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SUMMARY: 
Here, we present a protocol to produce large amounts of recombinant RNA in Escherichia coli by 
co-expressing a chimeric RNA that contains the RNA of interest in a viroid scaffold and a plant 
tRNA ligase. The main product is a circular molecule that facilitates purification to homogeneity. 
 
ABSTRACT: 
With increasing interest in RNA biology and the use of RNA molecules in sophisticated 
biotechnological applications, the methods to produce large amounts of recombinant RNAs are 
limited. Here, we describe a protocol to produce large amounts of recombinant RNA in 
Escherichia coli based on co-expression of a chimeric molecule that contains the RNA of interest 
in a viroid scaffold and a plant tRNA ligase. Viroids are relatively small, non-coding, highly base-
paired circular RNAs that are infectious to higher plants. The host plant tRNA ligase is an enzyme 
recruited by viroids that belong to the family Avsunviroidae, such as Eggplant latent viroid (ELVd), 
to mediate RNA circularization during viroid replication. Although ELVd does not replicate in E. 
coli, an ELVd precursor is efficiently transcribed by the E. coli RNA polymerase and processed by 
the embedded hammerhead ribozymes in bacterial cells, and the resulting monomers are 
circularized by the co-expressed tRNA ligase reaching a remarkable concentration. The insertion 
of an RNA of interest into the ELVd scaffold enables the production of tens of milligrams of the 
recombinant RNA per liter of bacterial culture in regular laboratory conditions. A main fraction 
of the RNA product is circular, a feature that facilitates the purification of the recombinant RNA 
to virtual homogeneity. In this protocol, a complementary DNA (cDNA) corresponding to the RNA 
of interest is inserted in a particular position of the ELVd cDNA in an expression plasmid that is 
used, along the plasmid to co-express eggplant tRNA ligase, to transform E. coli. Co-expression 
of both molecules under the control of strong constitutive promoters leads to production of large 
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amounts of the recombinant RNA. The recombinant RNA can be extracted from the bacterial cells 
and separated from the bulk of bacterial RNAs taking advantage of its circularity. 
 
INTRODUCTION:  
In contrast to DNA and proteins, protocols for easy, efficient and cost-effective production of 
large amounts of RNA are not abundant. However, research and industry demand increasing 
amounts of these biomolecules to investigate their unique biological properties1, or to be 
employed in sophisticated biotechnological applications, including their use as highly specific 
aptamers2, therapeutic agents3, or selective pesticides4. In vitro transcription and chemical 
synthesis are commonly used in research to produce RNA. However, these methods entail 
important limitations when large amounts of the products are required. The logical alternative is 
to use the endogenous transcription machinery of living cells, followed by a purification process 
to separate the RNAs of interest from the cellular companions. Following this strategy, methods 
have been developed to produce recombinant RNAs in bacterial cells, such as the lab-friendly 
Escherichia coli5 or the marine purple phototrophic alpha-proteobacterium Rhodovolum 
sulfidophilum6. Most methods to produce recombinant RNA in bacteria rely on the expression of 
a native highly stable RNA scaffold, such as a tRNA or an rRNA, in which the RNA of interest is 
inserted7. This imposes the necessity of releasing the RNA of interest out of the chimeric 
molecule, if the presence of extra RNA is a problem for the downstream applications8. Another 
concept in recombinant RNA biotechnology is the production of recombinant ribonucleoprotein 
complexes that may be the desired product per se or used as a protective strategy to increase 
the stability of the RNA of interest9,10. Similarly, the production of circular RNAs has also been 
suggested as a strategy to generate more stable products11. 
 
We have recently developed a new method to produce large amounts of recombinant RNA in E. 
coli that participates in three of the above concepts: the insertion of the RNA of interest in a 
highly stable circular RNA scaffold and the co-expression of the recombinant RNA with an 
interacting protein to likely produce a stable ribonucleoprotein complex that accumulates in 
remarkable amounts in bacterial cells12. In contrast to previous developments, we used an RNA 
scaffold completely alien to E. coli, namely a viroid. Viroids are a very particular type of infectious 
agents of higher plants that are exclusively constituted by a relatively small (246-401 nt) highly 
base-paired circular RNA13. Interestingly, viroids are non-coding RNAs and, with no help from 
their own proteins, they are able to complete complex infectious cycles in the infected hosts14. 
These cycles include the RNA-to-RNA replication in the nuclei or chloroplasts, depending on the 
viroid family Pospiviroidae or Avsunviroidae, respectively, movement through the infected 
plant and evasion of the host defensive response. Viroids must be ranked among the most stable 
RNAs in nature, as a consequence of being a naked circular RNA and having to survive in the 
hostile environment of plant infected cells. This property may make viroids particularly suitable 
as scaffolds to stabilize recombinant RNA in biotechnological approaches. In addition, the new 
method is based on co-expression of the viroid scaffold with an interacting plant protein. Viroids 
replicate through a rolling-circle mechanism in which host enzymes are recruited to catalyze the 
different steps of the process. Notably some viroids, more specifically those that belong to the 
family Avsunviroidae15, contain ribozymes that are also involved in replication. Depending on the 
viroid species, transcription of viroid RNAs is mediated by the host RNA polymerase II or the 
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chloroplastic nuclear-encoded RNA polymerase (NEP). Viroid RNA processing seems to be 
catalyzed by a host type-III RNase, although in viroids with ribozymes oligomeric RNA 
intermediates self-cleave during replication. Finally, the resulting viroid monomers are 
circularized, depending on the viroid family, by the host DNA ligase 1 or the chloroplastic isoform 
of tRNA ligase16,17. This last enzyme is involved in ligation of the monomeric forms of the viroids 
in the family Avsunviroidae, such as Eggplant latent viroid (ELVd)18. 
 
In the course of a work to analyze the sequence and structural requirements of ELVd that 
determine recognition by the eggplant (Solanum melongena L.) tRNA ligase, we set up an 
experimental system based on co-expression of both molecules in E. coli19. We noticed that 
longer-than-unit ELVd transcripts self-cleave efficiently in E. coli cells through the embedded 
hammerhead ribozymes and that the resulting viroid monomers with 5’-hydroxyl and 2’,3’-
phosphodiester termini were efficiently circularized by the co-expressed eggplant tRNA ligase. 
Even more, the resulting circular viroid RNA reached an unexpected high concentration in E. coli, 
exceeding those of the endogenous rRNAs12. Absence of replication intermediates indicated lack 
of ELVd RNA-to-RNA amplification in these bacterial cells. Interestingly, insertion of heterologous 
RNAs in a particular position of the viroid molecule had a moderate effect on accumulation of 
the circular viroid-derived RNAs12. These observations made us envision a method to produce 
large amounts of recombinant RNAs in bacteria. In this method, the cDNAs corresponding to the 
RNAs of interest are inserted in the ELVd cDNA and the resulting chimeric RNA is expressed in E. 
coli through a strong constitutive promoter. For the system to work, E. coli must be co-
transformed with a plasmid to express the eggplant tRNA ligase. The ELVd-derived longer-than-
unit transcript is processed by the embedded hammerhead ribozymes and the resulting 
monomers with the appropriate termini are recognized and circularized by the co-expressed 
tRNA ligase. This way, the RNA of interest is inserted into a very stable circular scaffold consisting 
of the viroid circular molecule. This recombinant chimeric RNA is most probably further stabilized 
inside the E. coli cells by formation of a ribonucleoprotein complex through interaction with tRNA 
ligase. Using this method (see protocol below), RNA aptamers, hairpin RNAs and other structured 
RNAs have been easily produced in amounts of tens of milligrams per liter of E. coli culture in 




1. Plasmid Construction 
 
1.1. Amplify by PCR (or by reverse transcription PCR if starting from an RNA template) the cDNA 
corresponding to the RNA of interest using primers with 5’ extension to allow assembly into the 
expression plasmid. Use a commercial kit. To avoid undesired mutations, use a high-fidelity DNA 
polymerase.  
 
1.1.1. To insert the cDNA in the expression plasmid by Gibson assembly20, add the following 5’ 




CCCTCCTAGGGAACACATCCTTGAXXXXXXXXXXXXXXXXXXXXXX-3’; X represents nucleotides 
homologous to the terminal ends of the RNA of interest.  
 
1.1.2. Incubate for 30 s at 98 °C, followed by 30 cycles of 10 s at 98 °C, 30 s at 55 °C and 30 s at 
72 °C, and a final extension of 10 min at 72 °C. 
 
1.2. Digest 100 ng of plasmid pLELVd-BZB with 10 U of the type-IIS restriction enzyme Bpi I for 1 
h at 37 °C in a 20-µL reaction in a 0.5-mL tube in buffer G (10 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 
50 mM NaCl, 0.1 mg/mL BSA).  
 
Note: All plasmids are available on request to the corresponding author. Bpi I is equivalent to Bbs 
I. 
 
1.3. Separate the PCR and digestion products by electrophoresis in a 1% agarose gel in TAE buffer 
(40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 7.2). Stain the gel for 15 min by shaking in 200-
mL of 0.5 µg/mL ethidium bromide. Visualize the DNA using a UV transilluminator and cut the 
bands corresponding to the amplified cDNA and the Bpi I-digested plasmid (2046 bp) using a 
scalpel blade.  
 
Note: Bpi I digestion of pLELVd-BZB also releases a 528-bp product corresponding to the LacZ 
blue-white reporter. 
 
1.4. Elute the DNAs from the gel fragments using silica gel columns (gel DNA recovery kit in Table 
of Materials) and quantify the DNA concentration by spectrophotometric analysis.  
 
1.5. Set up a Gibson assembly reaction using the amplified cDNA and the digested plasmid. Use 
a 3-fold molar excess of insert versus vector20. Incubate for 1 h at 50 °C and purify the reaction 
products using a silica gel column (DNA clean & concentrator kit in the Table of Materials). 
 
1.6. Use the purified products of the Gibson assembly reaction to electroporate competent E. coli 
DH5α cells. Using 1-mm electroporation cuvettes, apply the following settings: 1500 V and 5 ms. 
Incubate for 1 h at 37 °C in super optimized broth with catabolite repression (SOC; 20 g/L 
tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM glucose, pH 7.0) 
liquid medium and then spread onto Luria-Bertani (LB; 10 g/L tryptone, 5 g/L yeast extract, 10 
g/L NaCl) agar (1.5%) plates containing 50 µg/mL ampicillin.  
 
1.6.1. To screen for colonies corresponding to transformed E. coli clones that likely incorporated 
the insert, 15 minutes before plating the electroporated cells, spread 30 µL of 50 mg/mL 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) in dimethylformamide. Incubate plates 
overnight at 37 °C. 
 
1.7. Pick several white colonies and grow overnight at 37 °C in liquid LB media. Purify plasmids 
using a miniprep kit (see Table of Materials) and analyze their sizes by electrophoresis in a 1% 




1.8. Select the most likely recombinant plasmid based on electrophoretic migration compared to 
the pLELVd-BZB control. Confirm the sequence of the selected plasmid by sequencing using 
primers 5’-CCTTTTTCAATATTATTGAAGC-3’ and 5’-GATGCTCGTCAGGGGGGCGGAG-3’ that flank 
the whole expression cassette in pLELVd-BZB. 
 
Note: Remember that this plasmid contains a 528-bp polylinker with the LacZ marker that is 
replaced by the cDNA of interest. Restriction mapping may help to select the right recombinant 
plasmids. 
 
2. RNA Expression 
 
2.1. Co-electroporate (see conditions in 1.6) the selected E. coli strain (E. coli BL21 or a BL21 
derivative) with the pLELVd-BZB-derivative that contains the cDNA corresponding to the RNA of 
interest and plasmid p15LtRnlSm to co-express the eggplant tRNA ligase. Use the E. coli 
HT115(DE3), which lacks RNase III21, to express RNAs with long double-stranded regions.  
 
Note: Both the RNA of interest and the tRNA ligase mRNA are transcribed by the E. coli RNA 
polymerase. No DE3 lysogen to express T7 RNA polymerase is required in the E. coli strain, 
although the presence of this lysogen has no deleterious effects. 
 
2.2. After 1 h incubation at 37 °C in SOC liquid medium, plate electroporated bacteria in LB solid 
medium containing 50 µg/mL ampicillin and 34 µg/mL chloramphenicol. Incubate overnight at 37 
°C. 
 
2.3. Pick a colony and inoculate a 1-L baffled Erlenmeyer flask with 250 mL of liquid Terrific Broth 
(TB) medium (12 g/L tryptone, 24 g/L yeast extract, 0.4% glycerol, 0.17 M KH2PO4, and 0.72 M 
K2HPO4), containing 50 µg/mL ampicillin and 34 µg/mL chloramphenicol. Incubate at 37 °C with 
vigorous shaking at 180 revolutions per minute (rpm). Harvest bacteria between 12 and 16 h after 
culture inoculation. 
 
3. RNA Extraction and Purification 
 
3.1. For analytical purposes, take 2-mL aliquots of the culture at the desired time points and 
centrifuge at 14,000 x g for 2 min. Discard the supernatant and resuspend the cells in 50 µL of TE 
buffer (10 mM Tris-HCl, pH 8.0, and 1 mM EDTA) by vortexing.  
 
3.1.1. Add one volume (50 µL) of a 1:1 (v/v) mix of phenol (saturated with water and equilibrated 
at pH 8.0 with Tris-HCl, pH 8.0) and chloroform. Break the cells by vigorous vortexing and 
separate the aqueous and organic phases by centrifugation for 5 min at 14,000 x g.  
 
3.1.2. Carefully recover the aqueous phases (upper) that contains total bacterial RNA.  
 




3.2. For preparative purposes, pour culture into a 250-mL centrifuge bottle and spin down cells 
at 14,000 x g for 10 min. Discard supernatant. Wash the cells by resuspending in 30 mL of water. 
Transfer to a centrifuge tube and spin down cells again under the same conditions. 
 
3.3. Discard the supernatant and resuspend the cells in 10 mL of chromatography buffer (50 mM 
Tris-HCl, pH 6.5, 150 mM NaCl, 0.2 mM EDTA) by vortexing.  
 
Note: At this time, cells can be frozen at -20 °C to proceed with purification at any other moment. 
 
3.4. Using a fresh or thawed bacterial preparation, break cells by adding 1 volume (10 mL) of 
phenol:chloroform (see step 3.2) and vortexing vigorously. 
 
3.5. Centrifuge for 10 min at 12,000 x g, recover the aqueous phase and re-extract with 1 volume 
(10 mL) of chloroform under the same conditions.  
 
Note: The RNA preparation can be stored at -20 °C at this point. 
 
3.6. Further purify total bacterial RNA by anion-exchange chromatography. Filter the RNA 
preparation through a 45-µm syringe filter and load on a 1-mL diethylethanolamine (DEAE) 
column. 
 
3.6.1. For chromatography purification, use a liquid chromatography system at a flow rate of 1 
mL/min. Before sample loading, equilibrate the column with 10 mL of chromatography buffer 
(see step 3.3 for composition).  
 
3.6.2. Load the sample and wash the column with 10 mL of chromatography buffer. Elute RNA 
with 20 mL of elution buffer (50 mM Tris-HCl, pH 6.5, 1 M NaCl, 0.2 mM EDTA) and collect 1-mL 
aliquots.  
 
Note: RNA quickly elutes in the initial fractions. The column can be re-used for further 
purifications. For this, wash the column with 10 mL of water and store at 4 °C in 20% ethanol. 
 
3.7. Since a major part of the recombinant RNA accumulates in E. coli in a circular form, this 
property can be profited for purification to homogeneity12. Separate circular RNAs from the linear 
counterparts by two-dimensional polyacrylamide gel electrophoresis (2D PAGE) combining non-
denaturing and denaturing (8 M urea) conditions12,22. 
 
4. RNA Analysis 
 
4.1. Prepare a 5% polyacrylamide gel (37.5:1 acrylamyde:N,N’-methylenebisacrylamide, mass 




4.2. Mix 20 µL of RNA preparations with 1 volume (20 µL) of loading buffer (98% formamide, 10 
mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.0025% bromophenol blue, and 0.0025% xylene cyanol), 
incubate for 1.5 min at 95 °C in a heating block, and snap cool on ice. 
 
4.3. Load the samples in the polyacrylamide gel and run the electrophoresis at appropriate 
conditions depending on the gel dimensions (e.g., run 140 × 130 × 2 mm gels for 2.5 h at 200 V). 
Stain the gel for 15 min in 1 µg/mL ethidium bromide, wash with water, and visualize RNA under 
UV light.  
 
REPRESENTATIVE RESULTS:  
To produce recombinant RNA in E. coli using the ELVd-derived system12, the RNA of interest is 
grafted into an ELVd RNA scaffold. This chimeric RNA is co-expressed along the eggplant tRNA 
ligase in E. coli. Once processed, cleaved and circularized, the chimeric circular RNA, from which 
the RNA of interest protrudes, likely forms a ribonucleoprotein complex with the co-expressed 
eggplant enzyme that reaches remarkable concentration in the bacterial cells (Figure 1). 
Consequently, the first step to produce recombinant RNA using this system consists of inserting 
the cDNA corresponding to the RNA of interest into a particular position in the ELVd cDNA, T245-
T246 in the ELVd sequence variant AJ536613. Plasmid pLELVd-BZB, which contains a polylinker 
on this position with two Bpi I recognition sites and a LacZ blue/white marker gene, facilitates 
this insertion by the very efficient Gibson assembly method20. Selection of transformed E. coli 
clones containing the desired recombinant plasmids is facilitated by the blue/white screening of 
LacZ marker. Plasmids in which the double Bpi I digestion was incomplete and could not 
incorporate the insert likely produce blue colonies in the presence of X-gal. Figure 2 shows the 
electrophoretic analysis of several recombinant plasmids in which different cDNAs were inserted. 
These plasmids show different migrations when compared to pLELVd-BZB. Note that pLELVd-BZB 
contains the LacZ marker (528 bp) that is replaced by the cDNA corresponding to the RNA of 
interest. So, although this depends on the size of the inserted cDNA, the recombinant plasmids 
usually migrate faster than the control plasmid (Figure 2). 
 
The pLELVd-BZB-derivatives that contain the cDNAs corresponding to the RNAs of interest are 
used along p15LtRnlSm to co-electroporate E. coli. Co-transformed bacteria are selected on 
plates containing ampicillin and chloramphenicol. Then, selected E. coli clones are grown at 37 
°C with strong agitation in the rich TB medium. Under this culture conditions, production of the 
recombinant RNA is maximized12. The presence of the recombinant RNA in the bacteria can be 
easily monitored by breaking the cells with a mix of phenol and chloroform in the presence of a 
buffer and analyzing the RNA, which partitions in the aqueous buffer, by denaturing PAGE. Figure 
3 show ethidium bromide stained polyacrylamide gels in which total RNAs from different E. coli 
clones were separated. The pictures show strong bands that correspond to empty ELVd and 
chimeric ELVd forms in which different RNAs of interest were inserted. Interestingly we find a 
major fraction of the recombinant RNA as circular form. Using a combination of two PAGEs under 
denaturing conditions at high and low ionic strength, the circularity of the main fraction of the 




Depending on the downstream application, the total E. coli RNA preparation that contains the 
chimeric ELVd-RNA of interest may be the goal of the current protocol. However, when needed, 
the RNA preparation can be further purified by anion-exchange chromatography. Chromatogram 
in Figure 5 shows the efficient retention of E. coli RNA on the column at low ionic strength (150 
mM NaCl) and subsequent elution at high ionic strength (1 M NaCl). Most of the RNA is collected 
in fractions 2 and 3. To purify the recombinant RNA to homogeneity, advantage of circularity can 
be taken. Circular RNAs are delayed with respect to their linear counterparts in denaturing 
conditions22. These RNAs can be eluted from the gel after ethidium bromide staining. The use of 
a solubilizable polyacrylamide gel, such as those cross-linked with N,N’-bis(acryloyl)cystamine23, 







Figure 1: Schematic representation of the 
viroid-based system to produce 
recombinant RNA in E. coli. The cDNA 
corresponding to the RNA of interest (the 98-
nt-long RNA aptamer Spinach in the scheme) 
is inserted into plasmid pLELVd-BZB. E. coli is 
co-transformed with the pLELVd-BZB-
derivative and plasmid p15LtRnlSm to co-
express eggplant tRNA ligase. In E. coli, the 
chimeric ELVd-Spinach RNA transcript is self-
cleaved (red arrowheads) by the viroid 
hammerhead ribozymes. The resulting 
monomer is recognized by the co-expressed 
tRNA ligase and circularized. The 
recombinant RNA consists of a circular viroid 
scaffold from which the RNA of interest (in 
green) protrudes. Accumulation of the recombinant RNA to large amounts in E. coli likely results 
from stabilization of the ribonucleoprotein complex with tRNA ligase. In addition to the split ELVd 
cDNA, plasmid pLELVd-BZB contains a pUC replication origin (pUC ori), an ampicillin selection 
gene (AmpR), the E. coli murine lipoprotein (lpp) promoter and rRNA (rrnC) terminator, and the 
LacZ marker. Plasmid p15LtRnlSm contains a p15A replication origin (p15A ori), a 
chloramphenicol resistance gene (CmR), the E. coli lpp promoter and a phage T7 transcription 




Figure 2: Electrophoretic analysis of pLELVd-
BZB-derived expression plasmids that 
contain different cDNAs of interest. 
Plasmids were separated by electrophoresis 
in a 1% agarose gel that was stained with 
ethidium bromide. Lane 1, DNA marker with 
sizes in kbp of some of the components on 
the left; lane 2, pLELVd-BZB; lane 3, pLELVd-
BZB derivative to express an empty ELVd; 
lanes 4 to 7, pLELVd-BZB derivatives to 
express the RNA aptamer Spinach (lane 4), 
the streptavidin binding aptamer (lane 5), an 
RNA hairpin with a contiguous 42 bp double-
stranded region (lane 6), and the 3’ cap-
independent translation enhancer (CITE) of a 
plant virus (lane 7).  
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Figure 3: Recombinant RNA produced in E. 
coli using the viroid-based system. Total 
RNAs from different E. coli clones were 
extracted by treatment with 
phenol:chloroform and aliquots separated by 
denaturing PAGE. Gels stained with ethidium 
bromide are shown. Recombinant RNAs were 
produced in E. coli (A) BL21(DE3) and (B) 
HT115(DE3). (A and B) Lanes 1, RNA marker 
with sizes in nt on the left; lanes 2, RNAs from 
E. coli clones to express an empty ELVd (333 
nt). (A) Lanes 3 and 4, RNAs from E. coli 
clones to express a chimeric ELVd form 
containing the aptamer Spinach (98 nt) and 
the streptavidin binding aptamer (42 nt), 
respectively. (B) Lane 3, RNAs from an E. coli 
clone to express a chimeric ELVd form 
containing a 42-bp-long double stranded 








Figure 4: Circularity of the recombinant RNA 
produced in E. coli using the viroid-based 
system. Total RNAs from an E. coli clone to 
express a chimeric ELVd that contains the 
aptamer Spinach were separated by 2D 
denaturing PAGE first under high and then 
under low ionic strength. The gels were 
stained with ethidium bromide. The blue 
arrows indicate directions of electrophoretic 
migration. The red arrow points to the 
circular ELVd-Spinach that is selectively 
delayed from the linear counterparts of the 





Figure 5: Chromatographic purification of a 
recombinant RNA produced in E. coli using 
the viroid-based system. Total RNAs from an 
E. coli clone that produces a chimeric ELVd-3’ 
CITE (55 nt) were loaded on a DEAE 
chromatography column that was washed in 
the presence of 150 mM NaCl. RNA was 
eluted in the presence of 1 M NaCl. The 
chromatogram shows absorbance at 254 nm 
(blue line) and conductivity in mS/cm (orange line) versus volume. The different steps of the 
chromatographic separation (equilibration, injection, wash, elution and column regeneration) 







Figure 6: Purification to homogeneity of a 
recombinant RNA produced in E. coli using 
the viroid-based system. Total RNAs from an 
E. coli clone that produces a chimeric ELVd-3’ 
CITE were first purified by chromatography 
using a DEAE-Sepharose column and then 
separated by 2D PAGE. First gel was run 
under denaturing conditions (8 M urea, 
buffer TBE). After staining with ethidium 
bromide, the gel band that contains the 
circular form of the recombinant RNA was 
transferred to the top of a second gel that was run under non-denaturing condition (buffer TAE). 
The acrylamide of the second gel was cross-linked with N,N’-bis(acryloyl)cystamine, which 






While researching the ELVd sequence and structure requirements involved in the recognition by 
the eggplant tRNA ligase, we noticed that co-expression of both molecules in the non-host E. coli 
led to an unexpected large accumulation of viroid circular forms in bacterial cells19. We 
understood that the large accumulation of viroid RNA in E. coli most probably was the 
consequence of co-expressing a highly stable RNA molecule, such as the relatively small (333 nt), 
highly based-paired, circular viroid, and a protein for which this particular viroid displays high 
affinity. ELVd RNA must recruit the host tRNA ligase to mediate its circularization during 
replication in the infected plant17. Although we do not have experimental confirmation, we 
anticipate that both molecules form a ribonucleoprotein complex in E. coli that further stabilizes 
the viroid RNA and allows reaching the remarkable concentration of 150 mg per liter of bacterial 
culture that highly exceeds those of endogenous RNAs, such as rRNAs12. Since ELVd does not 
replicate in E. coli, we reasoned that insertion of a heterologous RNA was not going to 
dramatically affect accumulation of the viroid-derived RNA and, in fact, that was the case. This 
observation is the basis of the method to produce large amounts of recombinant RNA in E. coli 
that we describe here. The method uses the circular RNA molecule of ELVd as a scaffold on which 
the RNA of interest is presented. To produce a circular ELVd scaffold in E. coli, we need to express 
a precursor RNA with the duplicated domain of the viroid hammerhead ribozyme. ELVd 
ribozymes self-cleave very efficiently in E. coli and the resulting viroid monomers are recognized 
and circularized by the co-expressed tRNA ligase. Co-expression of the tRNA ligase is a key feature 
of the system. ELVd RNA is hardly detected in E. coli unless this particular enzyme is co-
expressed12. 
 
In our protocol, plasmid pLELVd-BZB allows to insert the cDNA corresponding to the RNA of 
interest by simple and efficient Gibson assembly between positions U245 and U246 of ELVd. This 
site corresponds to the terminal loop of a long hairpin present in the most likely ELVd 
conformation24,25. Insertion in this particular position must promote that the RNA of interest 
protrudes from the very stable scaffold formed by ELVd and must avoid intramolecular 
interaction between the RNA of interest and ELVd (Figure 1). We have not explored the effect of 
inserting the RNA of interest in alternative positions of the ELVd molecule. Plasmid p15LtRnlSm 
allows co-expression of the eggplant tRNA ligase. RNAs are transcribed in both plasmids under 
the control of a constitutive strong E. coli promoter, namely murein lipoprotein (lpp). This makes 
the system constitutive with no need of induction. However, we also build a similar plasmid 
(p15tRnlSm) to express the tRNA ligase under the control of the phage T7 RNA polymerase in an 
isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible system. Using this plasmid, accumulation 
of the recombinant RNA only occurs after induction of tRNA ligase expression by adding IPTG12. 
In the current system, the RNA of interest is expressed from a high copy number plasmid with 
pUC replication origin, while the tRNA ligase is expressed from a moderate copy number plasmid 
with p15A replication origin. Whether altering the copy number of both plasmids involved in the 
system improves accumulation of the recombinant RNA has not been explored so far. The size 
range of the RNA of interest admitted by the system has not been systematically investigated 





One of the reasons why production of recombinant RNA in vivo is not easy is most probably due 
to the intrinsic low half-life of RNA molecules. Our system is not alien to this problem. In fact, at 
a late E. coli growing phase, accumulation of recombinant RNA starts to decrease to virtually 
disappear12. This forces one to find the right window to harvest the cells. We observed, though, 
that this window is large enough to make the system friendly. However, we also observed that 
the optimum window depends on many factors including the particular E. coli strain, culture 
medium, growing conditions (agitation, volume of the flask, airing, etc.) and the physiological 
stage of the bacteria used to start the liquid culture. We recommend starting recombinant RNA 
production using fresh E. coli colonies from a plate inoculated the previous day and grown at 37 
°C. Storing plates in the fridge makes the harvest window more unpredictable. We obtained the 
most consistent results by starting liquid cultures with bacteria picked from a plate with a 
toothpick. The use of a liquid pre-culture, particularly if saturated, also drives to variability in the 
production protocol. 
 
Regarding purification, treatment of bacterial cells with phenol:chloroform is a very effective 
manner to break the cells and allows for the quantitative recovery of total bacterial RNA in the 
aqueous phase. Depending on the downstream application of the recombinant RNA, this 
aqueous phase or the preparation that results from precipitating the RNA from this aqueous 
phase with an alcohol may be enough. If further purification is needed, we recommend anion-
exchange chromatography using a DEAE anion exchange column (Figure 5). This purification step 
allows efficient removal of DNA and bacterial metabolites that also partitioned in the aqueous 
phase. If the downstream application of the recombinant RNA requires purification to 
homogeneity, the viroid-derived system offers a clear advantage when compared to other 
methods. Since a main fraction of the recombinant RNA is produced as a circular form, advantage 
of this property can be taken to separate it from the bulk of bacterial RNAs. Circular RNAs 
experience a delay in electrophoretic migration in denaturing conditions with respect to the 
linear counterparts of the same size22. This delay is more pronounced when the RNA is 
electrophoresed under lower ionic strength. In practice, circular RNAs can also been separated 
by two-dimensional denaturing PAGE under high and low ionic strengths (Figure 4). After 
electrophoretic separation, the recombinant RNA must be eluted from the gel. The use of a 
reversible cross-linker of acrylamide, such as N,N’-bis(acryloyl)cystamine23, facilitates recovery, 
particularly when purifying large amounts of RNA (Figure 6). Finally, if downstream application 
of the produced RNA demands separation of the RNA of interest from the viroid scaffold, our 
protocol does not offer any particular advantage to previous methods. The RNA of interest must 
be excised from the chimeric molecule using some of the previously described strategies, such as 
the use of ribozymes, DNAzymes or, possibly most efficient, the use of RNase H guided by two 
DNA oligonucleotides7. Trying to avoid this last cumbersome purification step, we have worked 
on trying to reduce the size of the viroid scaffold, although with partial success. We were able to 
produce notable amounts of recombinant RNA using viroid deleted forms (175, 215 and 246 nt) 
but increasing deletions of the viroid scaffold correlated with decreasing accumulation12. 
 
In sum, here a protocol is described to produce large amounts of recombinant RNA in E. coli that, 
to our knowledge, improves the yield of previously published methods. The protocol is based of 
co-expression in E. coli of the RNA of interest inserted into a viroid (ELVd) scaffold and the 
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eggplant tRNA ligase, the enzyme that circularizes this viroid in infected plants. A distinctive 
feature of our protocol is that recombinant RNA is mainly produced as a circular form, a property 
that facilitates purification to homogeneity for downstream applications. Using this protocol tens 
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Name Company Catalog Number Comments 
Phusion High-Fidelity DNA 
polymerase 
Thermo Scientific F530S  
Bpi I Thermo Scientific ER1011  
Agarose Conda 8010 D1 low EEO 
Tris PanReac AppliChem A1086,1000  
Acetic acid PanReac AppliChem 131008.1214  
EDTA Sigma-Aldrich E5134-500G  
Ethidium bromide PanReac AppliChem A1152,0025 1% 
Zymoclean Gel DNA Recovery Zymo Research D4001  
NanoDrop ThermoFisher Scientific ND-3300  
NEBuilder HiFi DNA Assembly 
Master Mix 
New England BioLabs E2621S  
DNA Clean & Concentrator Zymo Research D4003  
Eporator Eppendorf 4309000019  
Escherichia coli DH5α Invitrogen 18265-017  
Tryptone Intron Biotechnology Ba2014  
Yeast extract Intron Biotechnology 48045  
NaCl PanReac AppliChem 131659.1211  
Agar Intron Biotechnology 25999  
Ampicillin PanReac AppliChem A0839,0010  
X-gal Duchefa X1402.1000  
N,N-Dimethylformamide PanReac AppliChem 131785.1611  
NucloSpin Plasmid Macherey-Nagel 22740588.250  
Escherichia coli BL21(DE3) Novagen 69387-3  
Escherichia coli HT115(DE3)   Ref. Timmons et al., 2001 
Chloramphenicol Duchefa C 0113.0025  
Glycerol PanReac AppliChem 122329.1211 87% 
KH2PO4 PanReac AppliChem 131509.1210  
K2HPO4 PanReac AppliChem 122333.1211  
HCl PanReac AppliChem 131020.1211  
Phenol Scharlau FE04791000 90% 
Chloroform PanReac AppliChem A3691,1000  
Filtropur S 0.2 Sarstedt 83.1826.001  
HiTrap DEAE Sepharose FF 
column 
GE Healthcare Life Sciences 17-5055-01  
ÄKTAprime plus liquid 
chromatography system 
GE Healthcare Life Sciences 11001313  
Acrylamyde PanReac AppliChem A1089,1000 2K 
N,N’-methylenebisacrylamide Sigma-Aldrich M7279-100G  
Urea PanReac AppliChem 146392.1211  
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Boric acid PanReac AppliChem A2940,1000  
Formamide PanReac AppliChem A0937,2500  
Bromophenol blue Sigma-Aldrich B8026-5G  
Xylene cyanol Sigma-Aldrich X4126-10G  
N,N′-Bis(acryloyl)cystamine Sigma-Aldrich A4929-5G  
 
